BSL 02 1509AYM
Alternative Names: BSL02-1509AYMLatest Information Update: 28 Dec 2018
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Skin-disorders(In volunteers) in Japan (Topical)
- 20 Oct 2016 Kao Corporation completes a phase I trial in Skin disorders (In volunteers) in Japan (UMIN000019426)
- 01 Nov 2015 Preclinical trials in Skin disorders in Japan (Topical) prior to November 2015